<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01636180</url>
  </required_header>
  <id_info>
    <org_study_id>1.0, 2009-06-06</org_study_id>
    <nct_id>NCT01636180</nct_id>
  </id_info>
  <brief_title>Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.</brief_title>
  <acronym>REL-0609</acronym>
  <official_title>Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacja Ośrodek Badań Medycznych</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacja Ośrodek Badań Medycznych</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      REL-0609 trial's hypothesis is that repeated loading doses of clopidogrel (600 mg)
      administration in addition to high dose of clopidogrel continuous therapy (150 mg/day)
      results in higher inhibition of the platelets' aggregation in patients with myocardial
      infarction undergoing interventional treatment comparing to the standard therapy. Such
      treatment strategy will not cause increased risk of bleeding complications. In many trials
      treatment with to repeated loading doses of clopidogrel together with high dose of
      clopidogrel continuous therapy resulted in: MACE reduction, improvement of the long term
      therapy results, lower risk of ischemic complications. Currently, data regarding to the
      results of the above treatment are still limited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study is:

        -  to evaluate the effect of the repeated loading dose of clopidogrel (600 mg) in addition
           to high dose of clopidogrel continuous therapy (150 mg/day) on the platelet aggregation
           inhibition in patients with myocardial infarction undergoing interventional treatment

        -  to evaluate the safety of the repeated loading dose of clopidogrel (600 mg) in addition
           to high dose of clopidogrel continuous therapy (150 mg/day) in patients with myocardial
           infarction undergoing interventional treatment
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inhibition of platelet aggregation</measure>
    <time_frame>at 30 days follow-up</time_frame>
    <description>inhibition of platelet aggregation at the 30-day follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inhibition of platelet aggregation</measure>
    <time_frame>at 1st hour after administration of the repeated loading dose of clopidogrel / placebo</time_frame>
    <description>inhibition of platelet aggregation at 1st hour after administration of the repeated loading dose of clopidogrel / placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inhibition of platelet aggregation</measure>
    <time_frame>at 2nd hour after administration of the repeated loading dose of clopidogrel / placebo</time_frame>
    <description>inhibition of platelet aggregation at 2nd hour after administration of the repeated loading dose of clopidogrel / placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inhibition of platelet aggregation</measure>
    <time_frame>at 6th hour after administration of the repeated loading dose of clopidogrel / placebo</time_frame>
    <description>inhibition of platelet aggregation at 6th hour after administration of the repeated loading dose of clopidogrel / placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inhibition of platelet aggregation</measure>
    <time_frame>at 24th hour after administration of the repeated loading dose of clopidogrel / placebo</time_frame>
    <description>inhibition of platelet aggregation at 24th hour after administration of the repeated loading dose of clopidogrel / placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome</measure>
    <time_frame>30 days</time_frame>
    <description>frequency of bleeding complications within 30 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Clopidogrel - Repeated Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel - standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)</description>
    <arm_group_label>Clopidogrel - Repeated Loading Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)</description>
    <arm_group_label>Clopidogrel - standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        •≥18 years of age,

          -  Myocardial Infarction with or without ST segment elevation,

          -  clopidogrel treatment (confirmed administration of loading dose of 600 mg or chronic
             therapy of 75 mg/day),

          -  signed written informed consent.

        Exclusion Criteria:

          -  prior administration of fibrinolytic therapy and/or GP IIb/IIIa inhibitors within the
             last 14 days,

          -  prior administration of prasugrel within the last 14 days,

          -  subject with known hypersensitivity to the active ingredient or other components of
             the product

          -  increased risk of bleeding complications:bleeding diathesis, thrombocytopenia
             (platelet count &lt; 100 000/mm3), oral anticoagulant therapy (INR &gt;1.6), uncontrolled
             hypertension (systolic blood pressure &gt;200 mmHg), major bleeding, trauma or surgery
             within the last 30 days,

          -  acute renal failure,

          -  acute liver failure,

          -  pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Wojdyła, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii Carint Scanmed Sp. z o.o</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii Carint Scanmed Sp. z o.o</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>Areplex</keyword>
  <keyword>REL-0609</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

